O	0	8	Clinical
O	9	16	effects
O	17	19	of
B-intervention	20	26	shenqi
I-intervention	27	34	fuzheng
I-intervention	35	44	injection
O	45	47	in
O	48	51	the
O	52	63	neoadjuvant
O	64	76	chemotherapy
O	77	80	for
O	81	86	local
O	87	95	advanced
O	96	102	breast
O	103	109	cancer
O	110	113	and
O	114	117	the
O	118	125	effects
O	126	128	on
O	129	130	T
O	130	131	-
O	131	141	lymphocyte
O	142	149	subsets
O	149	150	.

O	151	153	To
O	154	162	evaluate
O	163	171	clinical
O	172	179	effects
O	180	182	of
O	183	189	shenqi
O	190	197	fuzheng
O	198	207	Injection
O	208	209	(
O	209	210	[
O	210	217	Chinese
O	218	228	characters
O	228	229	:
O	230	233	see
O	234	238	text
O	238	239	]
O	239	240	)
O	241	243	in
O	244	247	the
O	248	259	neoadjuvant
O	260	272	chemotherapy
O	273	276	for
O	277	282	local
O	283	291	advanced
O	292	298	breast
O	299	305	cancer
O	306	309	and
O	310	313	the
O	314	321	effects
O	322	324	on
O	325	326	T
O	326	327	-
O	327	337	lymphocyte
O	338	345	subsets
O	345	346	.

O	347	353	During
O	354	357	the
O	358	364	period
O	365	369	from
O	370	374	2000
O	375	377	to
O	378	382	2005
O	382	383	,
B-total-participants	384	387	126
B-eligibility	388	396	patients
I-eligibility	397	401	with
I-eligibility	402	407	local
I-eligibility	408	416	advanced
I-eligibility	417	423	breast
I-eligibility	424	430	cancer
O	431	435	were
O	436	443	treated
O	444	448	with
O	449	452	the
O	453	464	neoadjuvant
O	465	477	chemotherapy
O	477	478	.

O	479	483	They
O	484	488	were
O	489	497	randomly
O	498	505	divided
O	506	510	into
O	511	514	the
O	515	524	following
O	525	528	two
O	529	535	groups
O	535	536	:
O	537	538	a
B-control	539	546	control
I-control	547	552	group
O	553	555	of
B-control-participants	556	558	61
O	559	564	cases
O	565	572	treated
O	573	575	by
O	576	588	chemotherapy
O	589	594	alone
O	595	598	and
O	599	600	a
O	601	606	study
O	607	612	group
O	613	615	of
B-intervention-participants	616	618	65
O	619	624	cases
O	625	632	treated
O	633	635	by
O	636	648	chemotherapy
O	649	653	plus
O	654	660	shenqi
O	661	668	fuzheng
O	669	678	injection
O	678	679	.

O	680	683	All
O	684	687	the
O	688	693	cases
O	694	696	of
O	697	701	both
O	702	708	groups
O	709	713	were
O	714	719	given
O	720	723	the
O	724	727	CEF
O	728	729	(
O	729	732	CTX
O	733	736	500
O	737	739	mg
O	739	740	/
O	740	742	m2
O	742	743	,
O	744	746	d1
O	746	747	,
O	747	748	8
O	748	749	;
O	750	753	EPI
O	754	756	40
O	757	759	mg
O	759	760	/
O	760	762	m2
O	762	763	,
O	764	766	d1
O	766	767	,
O	768	769	8
O	769	770	;
O	771	774	and
O	775	776	5
O	776	777	-
O	777	779	Fu
O	780	783	500
O	784	786	mg
O	786	787	/
O	787	789	m2
O	790	792	d1
O	792	793	,
O	793	794	8
O	794	795	)
O	796	803	regimen
O	803	804	.

O	805	808	The
O	809	817	clinical
O	818	825	effects
O	825	826	,
O	827	830	the
O	831	838	effects
O	839	841	on
O	842	843	T
O	843	844	-
O	844	854	lymphocyte
O	855	863	subgroup
O	864	867	and
O	868	870	NK
O	871	876	cells
O	876	877	,
O	878	881	and
O	882	885	the
O	886	891	toxic
O	892	896	side
O	897	904	effects
O	905	909	were
O	910	918	observed
O	918	919	.

O	920	923	All
O	924	927	the
O	928	936	patients
O	937	946	completed
O	947	950	two
O	951	957	cycles
O	958	960	of
O	961	964	the
O	965	977	chemotherapy
O	977	978	,
O	979	982	and
O	983	986	the
O	987	995	efficacy
O	996	999	and
O	1000	1003	the
O	1004	1009	toxic
O	1010	1014	side
O	1015	1022	effects
O	1023	1027	were
O	1028	1037	evaluated
O	1037	1038	.

O	1039	1042	For
O	1043	1046	the
O	1047	1054	primary
O	1055	1060	tumor
O	1061	1063	in
O	1064	1067	the
O	1068	1074	breast
O	1074	1075	,
O	1076	1079	the
B-outcome	1080	1085	total
I-outcome	1086	1095	effective
I-outcome	1096	1100	rate
O	1101	1104	was
B-iv-bin-percent	1105	1107	69
I-iv-bin-percent	1107	1108	.
I-iv-bin-percent	1108	1109	2
I-iv-bin-percent	1109	1110	%
O	1111	1112	(
B-iv-bin-abs	1112	1114	45
O	1114	1115	/
B-intervention-participants	1115	1117	65
O	1117	1118	)
O	1119	1121	in
O	1122	1125	the
O	1126	1131	study
O	1132	1137	group
O	1138	1141	and
B-cv-bin-percent	1142	1144	49
I-cv-bin-percent	1144	1145	.
I-cv-bin-percent	1145	1146	2
I-cv-bin-percent	1146	1147	%
O	1148	1149	(
B-cv-bin-abs	1149	1151	30
O	1151	1152	/
B-control-participants	1152	1154	61
O	1154	1155	)
O	1156	1158	in
O	1159	1162	the
O	1163	1170	control
O	1171	1176	group
O	1177	1181	with
O	1182	1183	a
O	1184	1197	statistically
O	1198	1209	significant
O	1210	1220	difference
O	1221	1223	in
O	1224	1227	the
O	1228	1238	intergroup
O	1239	1249	comparison
O	1250	1251	(
O	1251	1255	chi2
O	1256	1257	=
O	1258	1259	5
O	1259	1260	.
O	1260	1263	251
O	1263	1264	,
O	1265	1266	P
O	1267	1268	=
O	1269	1270	0
O	1270	1271	.
O	1271	1274	022
O	1274	1275	,
O	1276	1277	<
O	1278	1279	0
O	1279	1280	.
O	1280	1282	05
O	1282	1283	)
O	1283	1284	.

O	1285	1290	There
O	1291	1294	was
O	1295	1297	no
B-outcome	1298	1309	progression
I-outcome	1310	1312	of
I-outcome	1313	1316	the
I-outcome	1317	1324	disease
O	1325	1327	in
O	1328	1332	both
O	1333	1336	the
O	1337	1343	groups
O	1343	1344	,
O	1345	1348	and
O	1349	1354	there
O	1355	1359	were
O	1360	1362	no
B-outcome	1363	1368	grade
I-outcome	1369	1371	IV
I-outcome	1372	1377	toxic
I-outcome	1378	1382	side
I-outcome	1383	1390	effects
O	1391	1393	in
O	1394	1397	the
O	1398	1401	two
O	1402	1408	groups
O	1408	1409	.

O	1410	1413	The
O	1414	1419	major
O	1420	1425	toxic
O	1426	1435	responses
O	1436	1440	were
B-outcome	1441	1457	myelosuppression
I-outcome	1458	1461	and
I-outcome	1462	1478	gastrointestinal
I-outcome	1479	1487	reaction
O	1487	1488	,
O	1489	1494	which
O	1495	1499	were
O	1500	1506	milder
O	1507	1509	in
O	1510	1513	the
O	1514	1519	study
O	1520	1525	group
O	1526	1530	than
O	1531	1534	the
O	1535	1542	control
O	1543	1548	group
O	1548	1549	,
O	1550	1553	and
O	1554	1558	with
O	1559	1560	a
O	1561	1568	shorter
O	1569	1577	recovery
O	1578	1584	course
O	1585	1587	in
O	1588	1591	the
O	1592	1598	former
O	1599	1603	than
O	1604	1607	the
O	1608	1614	latter
O	1614	1615	.

O	1616	1623	Besides
O	1623	1624	,
O	1625	1627	an
O	1628	1635	obvious
O	1636	1640	rise
O	1641	1643	of
O	1644	1647	the
O	1648	1649	T
O	1649	1650	-
O	1650	1660	lymphocyte
O	1661	1669	subgroup
O	1670	1673	and
O	1674	1676	NK
O	1677	1682	cells
O	1683	1686	was
O	1687	1692	found
O	1693	1695	in
O	1696	1699	the
O	1700	1705	study
O	1706	1711	group
O	1712	1717	after
O	1718	1721	the
O	1722	1733	neoadjuvant
O	1734	1746	chemotherapy
O	1746	1747	,
O	1748	1752	with
O	1753	1754	a
O	1755	1759	very
O	1760	1771	significant
O	1772	1782	difference
O	1783	1787	from
O	1788	1791	the
O	1792	1800	controls
O	1801	1802	(
O	1802	1803	P
O	1804	1805	<
O	1806	1807	0
O	1807	1808	.
O	1808	1810	01
O	1810	1811	)
O	1811	1812	.

O	1813	1819	Shenqi
O	1820	1827	fuzheng
O	1828	1837	Injection
O	1838	1841	can
O	1842	1849	improve
O	1850	1853	and
O	1854	1862	regulate
O	1863	1869	immune
O	1870	1878	function
O	1879	1881	of
O	1882	1885	the
O	1886	1894	patients
O	1895	1899	with
O	1900	1905	local
O	1906	1914	advanced
O	1915	1921	breast
O	1922	1928	cancer
O	1929	1934	given
O	1935	1938	the
O	1939	1950	neoadjuvant
O	1951	1963	chemotherapy
O	1963	1964	,
O	1965	1968	and
O	1969	1978	therefore
O	1979	1981	it
O	1982	1985	can
O	1986	1993	enhance
O	1994	1997	the
O	1998	2006	curative
O	2007	2013	effect
O	2014	2017	and
O	2018	2024	reduce
O	2025	2028	the
O	2029	2033	side
O	2034	2040	effect
O	2041	2043	as
O	2044	2048	well
O	2048	2049	.
